Premium
Prophylactic chemotherapy for hydatidiform mole five to 15 years follow‐up
Author(s) -
Kashimura Yoshiko,
Kashimura Masamichi,
Sugimori Hajime,
Tsukamoto Naoki,
Matsuyama Toshitaka,
Matsukuma Keita,
Kamura Toshiharu,
Saito Toshiaki,
Kawano Hideaki,
Nose Reiko,
Nose Yoshiaki,
Nakano Hito,
Taki Ichiro
Publication year - 1986
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19860801)58:3<624::aid-cncr2820580305>3.0.co;2-6
Subject(s) - medicine , chemotherapy , choriocarcinoma , complication , molar pregnancy , prophylactic treatment , surgery , trophoblastic neoplasm , chorioepithelioma , pregnancy , gestation , biology , genetics
The effectiveness of the prophylactic chemotherapy was evaluated in 420 patients with molar pregnancy. All patients were followed for 5 to 15 years after the evacuation. Twenty‐two (7.5%) of 293 patients with prophylactic chemotherapy and 23 (18.1%) of 127 patients without prophylactic chemotherapy (control) developed secondary trophoblastic disease. The prophylactic chemotherapy could reduce the occurrence of secondary trophoblastic disease. In these secondary trophoblastic diseases, 5 (22.7%) of 22 patients in the prophylactic chemotherapy group and 5 (21.7%) of 23 in the control had metastatic trophoblastic disease. Choriocarcinoma after the molar pregnancy developed in two patients (0.7%) of the prophylactic chemotherapy group and two (1.6%) of the control. Prophylactic chemotherapy did not eliminate the occurrence of choriocarcinoma. The complication of the prophylactic chemotherapy was seen in 27.3% of the patients. Neither severe complication nor death were related to the toxicity. Cancer 58:624‐629, 1986.